Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPR | P35270 | 2/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 7/20 | 0.41 |
| ▸ | CCNC | P24863 | 6/20 | 0.40 |
| ▸ | CDK8 | P49336 | 6/20 | 0.40 |
| ▸ | CDK19 | Q9BWU1 | 2/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11888917 | 0.84 | PDE10A (0.39) | PDE10ACCNCCDK8 | |
| SCHEMBL2384701 | 0.83 | PDE10A (0.50) | SPRPDE10A | |
| SCHEMBL1458202 | 0.78 | PDE10A (0.50) | PDE10A | |
| SCHEMBL9106126 | 0.78 | POLB (0.49) | PDE10A | |
| SCHEMBL1457781 | 0.77 | PLAT (0.43) | PDE10ACCNCCDK8JAK2NTRK1 | |
| SCHEMBL14672263 | 0.77 | POLB (0.47) | PDE10A | |
| SCHEMBL9104762 | 0.77 | L3MBTL1 (0.51) | PDE10A | |
| SCHEMBL1458473 | 0.76 | L3MBTL3 (0.43) | — | |
| SCHEMBL11889054 | 0.75 | KMT2A (0.46) | PDE10A | |
| SCHEMBL1458472 | 0.74 | HTT (0.52) | PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2649070-B1 | TRIAZOLOPYRIDINE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2014-09-17 | — | — | EP | disclosed |
| EP-2649070-A1 | TRIAZOLOPYRIDINE COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-10-16 | — | — | EP | disclosed |
| US-8349824-B2 | Triazolopyridine compounds | HOFFMANN-LA ROCHE INC. (US) | 2013-01-08 | — | — | US | disclosed |
| WO-2012076430-A1 | TRIAZOLOPYRIDINE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-14 | — | — | WO | disclosed |
| US-20120142665-A1 | TRIAZOLOPYRIDINE COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142665-A1 | TRIAZOLOPYRIDINE COMPOUNDS | PDE5A, PDE3A, PDE3B | SPR 968/4885PDE10A 7/4885CCNC 3432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.